Response to Waters et al. 'Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia ...' [5]

AIDS

Volumn 20, Issue 15, 2006, Pages 1991-1992

  Kan, Virginia L ^a   Gale, Howard B ^a   Shinol, Rebecca C ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ANALYTICAL EQUIPMENT; ANTIBIOTIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; REBOUND; VIREMIA; VIRUS INHIBITION; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; RNA, VIRAL; VIREMIA;

EID: 33748884505     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000247129.65623.d1     Document Type: Letter

References (4)

1. Waters L, Mandalia S, Asboe D. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml. AIDS 2006; 20:778-779.
2. Gale HB, Kan VL, Shinol RC. Performance of the TruGene human immunodeficiency virus type 1 genotyping kit and Open-Gene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter. Clin Vaccine Immunol 2006; 13:235-238.
3. Department of Health and Human Services Panel on Clinical Practice. Treatment of HIV infection: guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 6 October 2005. Available at: http:www.aidsinfo.nih.gov/guidelines. Accessed: August 2006.
4. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.